GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzex Neuropharma TRRI · USD

Materials · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Alzex Neuropharma — daily TRRI Delayed
Market value
$854
Last close × shares
Volume
13.1k
Shares, 5 Nov 2026
Price to earnings
0.0

About Alzex Neuropharma

Its shares trade under the ticker TRRI. It has been listed since 11 July 2001.

Trinity Resources, Inc. engages in the exploration and development of natural resource interests. The company is headquartered in Henderson, Nevada. The company went IPO on 2001-07-11. The firm is engaged in research and development targeting treatments of brain diseases. The company is also focused on chemical development of its new drugs dedicated to the symptomatic treatment of Alzheimer’s Disease but can be applied to other neurological diseases due to its platform technology.

Figures and description from our data supplier, not checked against the company's own report.

More about Alzex Neuropharma →

Latest on Alzex Neuropharma

Our reporting

We have not reported on Alzex Neuropharma yet.

Other Materials listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Alzex Neuropharma's ticker?

Alzex Neuropharma trades as TRRI on its US listing, under ISIN US89656L1035.

What was Alzex Neuropharma's last closing price?

0.00 on 5 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.